Wall Street Researcher

PRESSURE BIOSCIENCES INC

PBIO OTCQB

STRONG FY 2021

BREAKOUT TERRITORY – BUYING OPPORTUNITY !

Planet Micro Vegas – PBIO Fact SheetSpeaker Details Wed 11;30 AM

Strong Market Demand Fuels Company’s Decision to Access Early Revenue Generating Opportunities for UST Processing of High Quality Nanoemulsions of Oil-Based Active Ingredients for Multiple Markets Ahead of Q4 2022 Commercialization – Company Expects Several Executed Contracts During Q2 2022

These shares have spiked to the upside  on STRONG Financials . We feel that the 200 day M/A of $2.41 could be tested to the upside  soon. Average daily volume is 31,127 shares for the same 200 day period .

A superior management team is driving these shares higher discovering new uses for their medical device and achieveing record sales for March 2022 – Ultra Shear Tech Platform

We feel that a BUYING OPPORTUNITY is now at hand . All serious investors must place these shares on their BUY LIST and watch carefully for an UPSIDE BREAKOUT – Our Target $3.50

Research Report – Pressure BioSciences  – PBIO OTC

Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC Cell :    516 – 455-7662 – EMAIL – gzplumtree@gmail.com  WATCH THIS MOST RECENT INVESTOR  VIDEO WITH PRESSURE BIOSCIENCE CEO RIC SCHUMACHER  

MOMENTUM PLAY   – ARCHER INVESTMENT BUYS PBIO

Pressure BioSciences Announces Early Access Program for UST Nanoemulsion Processing

Strong Market Demand Fuels Company’s Decision to Access Early Revenue Generating Opportunities for UST Processing of High Quality Nanoemulsions of Oil-Based Active Ingredients for Multiple Markets Ahead of Q4 2022 Commercialization – Company Expects Several Executed Contracts During Q2 2022

SOUTH EASTON, MA / ACCESSWIRE / April 27, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced the initiation of an Early Access Program (effective July 1, 2022) for the use of its revolutionary Ultra Shear Technology™ (“UST™”) platform for the processing of oil-based active ingredients into highly stable, water soluble, long-term stable nanoemulsions.

In September 2021, and reinforced several times since, the Company announced plans for the commercialization of its revolutionary UST platform. Under this plan, commercialization activities are to begin with the opening of two fee-for-service, GMP-compliant tolling centers in the 2022 fourth quarter. These centers are to be located in the Boston and San Francisco areas. Good progress continues to be made in this effort.

Importantly however, PBI has been experiencing more immediate demand for UST-processed nanoemulsions. Although the UST platform systems and laboratory space required for the tolling sites will not be available until later in 2022, the Company currently has three working benchtop, small-capacity systems (BaroShear MINI) and expects to soon finish the manufacture of both a mid-capacity BaroShear K45 and a large-capacity BaroShear MAX (capable of very large production runs). Propelled by this very welcomed demand to use the UST platform, and aware that such use could help to accelerate the trajectory of commercial proof of principle, production engagement, and conversion into long term processing relationships with a diverse group of prospective partners in the nutraceutical, health and beauty, agrochem, and food/beverage industries, PBI has decided to open up a program to allow early access to the UST processing system.

Mr. John B. Hollister, Director of Sales and Marketing at PBI, addressed the burgeoning demand for access to PBI’s UST platform for processing valuable oil/water emulsion-based products in multiple major markets: “We have announced our plans to have commercial toll-production UST-processing capacity operational on the East and West coasts of the USA by Q4 2022. Since announcing this, we have worked closely with a number of companies on formulating some of their products. As a result, the demand to serve initial contracts for pilot-scale production of nanoemulsions in nutraceuticals, cosmetics, health and beauty care, and agrochemical markets has become particularly intense and is growing. We anticipate the announcement of at least two significant relationships and contracts within these sectors during Q2 2022, for which early small-batch production capacity can be pivotal to accelerating the commercialization phase to follow.”

Dr. Alexander Lazarev, Chief Science Officer at PBI, said: “UST, by design, is a scalable and precisely controlled process that allows us to “dial in” and routinely deliver sub100 nm nanoemulsions of desired characteristics. Resulting oil droplets become smaller than the wavelength of visible light, at which point the previously cloudy/opaque emulsions become transparent nanoemulsions. More importantly, oil-soluble bioactive molecules are now in nano-droplets so small that they become more readily absorbable and bioavailable. Taste and smell characteristics are similarly magnified, while textures are ultimately transformed into silkiness and lower viscosity. Most microorganisms are also destroyed in the process, yielding room-temperature stability against spoilage without a need for preservatives. Moreover, nanoemulsions are easily sterilized by filtration, which makes them ideal media for pharmaceutical drug delivery. These nanoemulsions exhibit remarkable stability against physical separation when prepared using our minimal custom formulations of plant-based, non-GMO, non-allergenic, organic/green natural stabilizers designed for clean label products.”

PBI’s President and CEO, Mr. Richard T. Schumacher, expanded: “Our early demonstrations of UST processing have astonished our prospective partners, including prednisone for pharmaceuticals; retinol for cosmetics; neem oil for agrochem; and astaxanthin, curcumin, krill oil, algae oil, and CBD for nutraceuticals. Retained samples were subjected to stability testing, and such testing has helped confirm that stability was completely maintained with full clarity at the key two-year milestone. We have demonstrated our ability to deliver these results at production scales from our BaroShear Mini to our K45 and MAX systems. Our first MAX system has been operational at the renowned Pilot Test Lab of The Ohio State University since January, and we anticipate that our consortium partnership with Ohio State will shortly launch into close working relationships on UST with diverse major global companies in the liquid food and beverage industry. Our plans remain on track to complete the development of four additional MAX systems and begin offering UST tolling services in East/West coast facilities by Q4 2022. Finally, we now have seven issued UST patents and believe that more will be awarded to us over the coming months.”

Mr. Schumacher concluded: “The PBI Team has been extraordinarily driven and focused, which has been instrumental in moving the UST platform from a critical R&D project to the point where we are just months away from proving the commercial viability, scalability, and the incredible product quality generated by the UST platform. Progress for PBI has been exciting as we have laid the foundations for UST over the past several years and we remain driven by our belief that without a doubt the best is yet to come.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Pressure BioSciences Leveraging Strong FY2021 Operational and Financial Successes, Worldwide Customer Base, Substantial IP Estate, and Three Powerful Technology Platforms to Accelerate Strategic Company Transformation in 2022

Q4 and FY2021 Total Revenue Increased 91% and 64% Respectfully Over Same Periods in 2020;
PCT, BaroFold, and PBI Agrochem Groups Scored Important Gains in 2021;
UST Platform Achieved Critical 2021 Goals – Discussions Ongoing with Key Leaders in Multiple Markets

Investor Conference Call Scheduled for Tuesday April 5 at 4:30 PM ET

SOUTH EASTON, MA / ACCESSWIRE / April 5, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotherapeutics, nutraceuticals, cosmetics, agrochem, food & beverage, and other industries, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, provided a business update, and offered guidance on the Company’s strategic changes and growth acceleration planned for FY 2022.

Over the past 15 years, PBI has acquired a wealth of knowledge and experience in the use of pressure to create remarkable results in a variety of commercially-attractive areas using the Company’s three enabling technology platforms: Pressure Cycling Technology (“PCT”), BaroFold™, and Ultra Shear Technology™ (“UST™”).

Jeffrey N. Peterson, Chairman of the PBI Board, set the stage for PBI’s exciting future: “The PCT and BaroFold technologies have provided important early opportunities for commercial traction, as PBI forged scientific understanding and acceptance for its high-pressure platforms. Building on multiple peer-reviewed opinion leader scientific articles and presentations, accelerating instrument installations, and expanding paid research projects, these platforms are expected to generate important sales growth in 2022 and beyond. In addition, we believe the UST platform is opening up a new, game-changing growth trajectory with its promise for revolutionizing massive global markets from pharmaceuticals, nutraceuticals, cosmetics, agrochem, food/beverage processing, and more.”

Richard T. Schumacher, President and CEO of PBI, continued the thought: “As we evaluated the prospective commercial successes for our technologies and products, UST singularly stood out. After extensive development efforts and due diligence, we came to understand that the proprietary UST platform is a disruptive technology with revenue potential that we believe can be transformative for PBI and the major markets it will serve. We have consequently focused the majority of the PBI Team’s 2021 efforts on UST development and on the commercial introduction and acceleration for UST in 2022.”

Mr. John Hollister joined the PBI Team as Director of Marketing and Sales in 2020. He came to PBI with broad experience in leading commercialization of major products in large companies like SmithKline (now GSK) and Amgen, as well as in the start-up world for the previous 17 years. His diverse experience in successfully developing and leading marketing programs (including initial product commercialization) with both large and modest budgets will be pivotal for PBI, as he leads our UST commercialization program. He is already driving the planning and execution of critical partnering and initial commercialization strategies in order to build rapid and robust customer adoption and to accelerate growth in 2022.

Mr. Hollister said: “The amazing PBI Team has spent years becoming experts in how to safely capture and utilize pressure to improve existing methods in research and pharmaceutical manufacturing. With the 2022 commercialization of UST, PBI will introduce to the world the full potential of what pressure can do in a variety of large and growing markets. The coming months will be a very exciting time for PBI, our customers, and for the users of their UST-processed products.”

Financial Results: Q4 2021 vs. Q4 2020

  • Total revenue for Q4 2021 was $315,199 compared to $164,702 for the same period in 2020, a 91% increase. This increase was primarily due to our double-digit growth in products and services.
  • Sales of instruments increased to $115,784 in Q4 2021 compared to $0 in Q4 2020.
  • Consumable sales were $82,680 for Q4 2021 compared to $48,651 for the same period in 2020, a 70% increase.
  • Operating loss for Q4 2021 was $1,221,148 compared to $1,041,293 for the same period in 2020, primarily due to increases in general and administrative expense.
  • Loss per common share – basic & diluted – decreased to $(0.48) for Q4 2021 from $(1.19) for Q4 2020.

Financial Results: FY2021 vs. FY2020

  • Total revenue for FY 2021 was $2,002,365 compared to $1,220,591 for FY2020, a 64% increase. This increase was primarily due to our growth in products and services.
  • Sales of instruments increased to $1,105,268 for FY 2021 compared to $568,457 for FY 2020, an increase of 94%
  • Consumable sales were $274,108 for the year ended December 31, 2021 compared to $204,889 for the same period in 2020, an increase of $69,219 or 34%.
  • Operating loss for FY 2021 was $4,185,147 compared to $4,585,787 for FY 2020. This decrease was primarily due to increases in total revenue.
  • Loss per common share – basic and diluted – decreased to $(3.42) for FY2021 from $(5.32) for the 2020 fiscal year.

Operational & Technical Highlights (2021/2022)

  • Solid progress reported on FY 2022 key goals.
  • Ohio State installs/commissions BaroShear MAX UST processing equipment at renowned Food Pilot Plant.
  • UST processing achieves 18-month stability of CBD oil nanoemulsion.
  • Five UST patents awarded, including two for critical nanogap valve.
  • Strong demand observed for our BaroFold protein refolding platform specialty testing services.
  • UST successfully transforms Neem Oil into a novel highly potent nanoemulsion for effective agrochem use.
  • UST demo and manufacturing sites (Fall 2022) named: Boston, MA and Mountain View, CA.
  • PBI establishes wholly-owned PBI Agrochem subsidiary.
  • UST platform successfully processes one of the world’s most potent antioxidants: Astaxanthin.
  • PBI and Ohio State University announce partnership in the formation of a food industry consortium to advance commercialization of the UST platform.

Earnings Call and Business Update

The Company will hold an Earnings Conference Call and Business Update at 4:30 PM ET on Tuesday, April 5, 2022. To attend this teleconference via telephone, Dial-in: (888) 506-0062 (North America), (973) 528-0011 (International). Verbal Passcode: 648452 or say Pressure BioSciences Fourth Quarter and Fiscal Year 2021 Financial Call. Replay Number (877) 481-4010; (919) 882-2331 (International). Replay Passcode: 45153. Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

For the Three Months Ended For the Year Ended
December 31, December 31,
2021 2020 2021 2020
Revenue:
Products, services, other
$ 315,199 $ 164,702 $ 2,002,365 $ 1,220,591
Total revenue
315,199 164,702 2,002,365 1220,591
Costs and expenses:
Cost of products and services
171,278 25,813 942,383 582,854
Research and development
262,437 335,696 1,101,509 1,143,420
Selling and marketing
72,519 125,197 324,728 649,783
General and administrative
1,030,113 719,289 3,818,892 3,430,321
Total operating costs and expenses
1,536,347 1,205,995 6,187,512 5,806,378
Operating loss
(1,221,148 ) (1,041,293 ) (4,185,147 ) (4,585,787 )
Other (expense) income:
Interest expense, net
(2,925,935 ) (2,842,964 ) (14,450,241 ) (8,344,236 )
Unrealized (loss) gain on investment in equity securities
(52,574 ) 13,635 (457,025 ) 500,358
Gain/(loss) on extinguishment of liabilities
320,042 (333,506 ) (1,061,073 ) (3,575,878 )
Total other expense
(2,658,467 ) (3,162,835 ) (15,968,339 ) (11,419,756 )
Net loss
(3,879,615 ) (4,204,128 ) (20,153,486 ) (16,005,543 )
Deemed dividend on beneficial conversion feature
(61,180 ) (873,798 ) (61,180 )
Preferred stock dividends
(418,640 ) (399,461 ) (1,658,175 ) (1,517,987 )
Net loss attributable to common shareholders
$ (4,298,255 ) $ (4,664,769 ) $ (22,685,459 ) $ (17,584,710 )
Net loss per common share – basic and diluted
$ (0.48 ) $ (1.19 ) $ (3.42 ) $ (5.32 )
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation
8,921,086 3,907,046 6,636,523 3,304,187

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS

December 31, 2021 December 31, 2020
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$ 132,311 $ 18,540
Accounts receivable
154,746 131,228
Inventories, net of $342,496 reserve at December 31, 2021 and December 31, 2020
1,147,554 592,767
Prepaid expenses and other current assets
422,617 314,936
Total current assets
1,857,228 1,057,471
Investment in equity securities
59,976 517,001
Property and equipment, net
115,846 16,490
Right of use asset leases
395,565 221,432
Intangible assets, net
403,846 490,385
TOTAL ASSETS
$ 2,832,461 $ 2,302,779
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts payable
$ 527,924 $ 771,945
Accrued employee compensation
117,680 417,578
Accrued professional fees and other
1,955,672 2,037,806
Other current liabilities
7,757,217 6,330,722
Deferred revenue
37,124 47,328
Convertible debt, net of unamortized discounts of $1,536,649 and $3,948,167, respectively
12,839,813 7,545,670
Other debt
1,256,840 1,135,469
Operating lease liability
132,996 65,193
Other related party debt
166,000
Total current liabilities
24,625,266 18,517,711
LONG TERM LIABILITIES
Long term debt
150,000 527,039
Operating lease liability – long term
262,569 156,239
Deferred revenue
3,587 19,382
TOTAL LIABILITIES
25,041,422 19,220,371
STOCKHOLDERS??? DEFICIT
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 300 shares issued and outstanding on December 31, 2021 and 2020, respectively (Liquidation value of $300,000)
3 3
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; 80,570 shares issued and outstanding on December 31, 2021 and 2020, respectively
806 806
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 10,000 shares issued and outstanding on December 31, 2021 and 2020, respectively
100 100
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; 21 shares issued and outstanding on December 31, 2021 and 2020, respectively
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; 3,458 shares issued and outstanding on December 31, 2021 and 2020, respectively
35 35
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; 6,880 shares issued and outstanding on December 31, 2021 and 2020, respectively
68 68
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 8,649 and 8,043 shares issued and outstanding on December 31, 2021 and 2020, respectively
87 81
Convertible Preferred Stock
Common stock, $.01 par value; 100,000,000 shares authorized; 9,120,526 and 4,168,324 shares issued and outstanding on December 31, 2021 and 2020 respectively
91,206 41,683
Warrants to acquire common stock
31,715,154 29,192,471
Additional paid-in capital
64,261,048 50,312,968
Accumulated deficit
(118,277,468 ) (96,465,807 )
Total stockholders’ deficit
(22,208,961 ) (16,917,592 )
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
$ 2,832,461 $ 2,302,779

Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN  or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN  or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. Writer charges PBIO a fee of $950 per month . All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly